Abbreviations 2M: Beta-2-microglobulin CAPP: Concerted Action Polyp Prevention CEA: Carcinoembryonic antigen CI: Confidence interval CRC: Colorectal cancer CTLA-4: Cytotoxic T-lymphocyte antigen 4 dMMR: Mismatch repair deficient EMT: Epithelialmesenchymal transition FDA: US Food and Drug Administration FSP: Frameshift peptide HDAC: Histone deacetylase HNPCC: Hereditary non-polyposis colon cancer HPV: Human papillomavirus ICI: Immune checkpoint inhibitor KIR2DL1: Killer cell immunoglobulin-like receptor 2DL1 LS: Lynch syndrome LS-CRCs: Lynch syndromeassociated colorectal cancers MAb: Monoclonal antibody MLH1: mutL homolog 1 MSH2: mutS homolog 2 MSH6: mutS homolog 6 MMR: Mismatch repair MSI: Microsatellite instability MSS: Microsatellite stability MUC1: Mucin 1 NK: Natural killer NSAID: Nonsteroidal anti-inflammatory drug OS: Overall survival PD-L1: Programmed death-ligand 1 PFS: Progression-free survival PMS2: Post-meiotic segregation increased 2 TIL: Tumor-infiltrating lymphocyte TME: Tumor microenvironment Treg: Regulatory T cell References Papers of particular interest, published recently, have been highlighted as: Of major importance Le DT, Kim TW, Van Cutsem E, Geva R, Jager D, Hara H, et al

No fillers, no flow agents beyond what's truly necessary
One such breakthrough is AOD9604 , an innovative therapy thats setting a new standard in weight management
Serious adverse effects in the infant are unlikely unless the mother has toxic serum theophylline concentrations
All Rights reserved
Imam Aliagan A, Madungwe NB, Tombo N, et al